发明申请
US20140235622A1 PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
有权
作为用于治疗相关疾病的5-HT2A丝氨酸受体的调节剂的主要氨基酸及其衍生物
- 专利标题： PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
- 专利标题（中）： 作为用于治疗相关疾病的5-HT2A丝氨酸受体的调节剂的主要氨基酸及其衍生物
-
申请号： US14166511申请日： 2014-01-28
-
公开(公告)号： US20140235622A1公开(公告)日： 2014-08-21
- 发明人: Bradley Teegarden , Dennis Chapman , Juyi Choi , Konrad Feichtinger , Sangdon Han , Honnappa Jayakumar , Thuy-Anh Tran , Jay Xu , Ning Zou
- 申请人： Bradley Teegarden , Dennis Chapman , Juyi Choi , Konrad Feichtinger , Sangdon Han , Honnappa Jayakumar , Thuy-Anh Tran , Jay Xu , Ning Zou
- 申请人地址： US CA San Diego
- 专利权人： Arena Pharmaceuticals, Inc.
- 当前专利权人： Arena Pharmaceuticals, Inc.
- 当前专利权人地址： US CA San Diego
- 主分类号： C07D417/12
- IPC分类号： C07D417/12 ; C07D401/12 ; C07D231/16 ; C07D413/12 ; C07D403/12 ; C07D409/12 ; C07D405/12 ; C07D231/12
摘要：
The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.The present invention also relates to the methods for the treatment of 5-HT2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.